Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 31Neoplasms 17Multiple Myeloma 9Thyroid Neoplasms 8Hematologic Neoplasms 7Thyroid Carcinoma, Anaplastic 6Carcinoma, Non-Small-Cell Lung 6Brain Neoplasms 6Lymphoma 5Glioma 5Colorectal Neoplasms 5Thyroid Cancer, Papillary 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neurofibromatosis 1 3Leukemia, Myeloid, Acute 3Biliary Tract Neoplasms 3Astrocytoma 3Adenocarcinoma, Follicular 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Skin Neoplasms 2Neurofibroma, Plexiform 2Neoplasm Metastasis 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Breast Neoplasms 2

Interventions

Ipilimumab 10pembrolizumab 7Nivolumab 7incomplete Freund's adjuvant 6Temozolomide 5Dacarbazine 5tebentafusp 4Sunitinib 4MART-1 Antigen 4Carboplatin 4CTLA-4 Antigen 4sargramostim 3montanide ISA 51 3aflibercept 3Paclitaxel 3Bevacizumab 3trametinib 2relatlimab 2olaparib 2lenvatinib 2cediranib 2Vorinostat 2Thalidomide 2Taxes 2Sorafenib 2Radiosurgery 2MAGEA3 protein, human 2Lenalidomide 2Interleukin-2 2Interleukin-12 Subunit p35 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Uveal Melanoma × trametinib × Clear all
NCT01979523 2026-04-13

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
42 enrolled 13 charts
Dermatologic

Uveal Melanoma

NCT01328106 2017-12-12

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

GlaxoSmithKline

Phase 2 Withdrawn
Dermatologic

Uveal Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡